UC-II® was recently mentioned in Chain Drug Review as a “promising innovation” within the joint health segment. The magazine points out that joint relief sales have been sinking as of late, and manufacturers have been searching for solutions in order to stimulate this $500 million segment.
Industry analyst Kurt Jetta suggests that UC-II® is the solution. He highlights in his article the 60% growth of products that include this proprietary form of undenatured type II collagen. Reckitt Benckiser and NBTY, major players in the supplement industry, both sell products that include UC-II® and are filling up shelves in retail stores all over. “The fact that the growth has come from both distribution gains and velocity gains suggests that these products continue to find an audience and are poised for continued dynamic growth,” says Jetta.
InterHealth CEO and President Paul Dijkstra is also quoted in the article: “We are trying to reactivate interest in joint relief by offering something other than traditional glucosamine derivatives…UC-II is a research-based ingredient that provides the efficacy consumers need with a smaller, easier-to-swallow pill size.”
For more information about InterHealth or UC-II® contact us at firstname.lastname@example.org or call us at 1-800-783-4636.
Office: 5451 Industrial Way
Benicia, CA 94510